NeurologyLive® Friday 5 — May 12, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: A New World: Digitally Assessing Cognitive Decline and Innovating the Clock Drawing Test

Digital technologies like the DCTclock are revolutionizing the way clinicians across all specialties can quickly assess for cognitive decline, an issue in today's aging society.

2: Peer Exchange: EDS and Narcolepsy Treatment Options

In episode 8 of this Peer Exchange series on "Advances in the Management of Excessive Daytime Sleepiness and Narcolepsy", neurology experts discuss excessive daytime sleepiness (EDS) and narcolepsy treatment options.

3: NeuroVoices: Sean Pittock, MD, on How Ravulizumab’s Effectiveness Speaks to Progress in NMOSD

In the latest edition of our in-depth Q&A series, the director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided perspective on a phase 3 study of patients with NMOSD in which no relapses were recorded while on ravulizumab.

4: Detecting Parkinson Disease at Early Stages With Alpha-Synuclein Amplification Assay: Russell Lebovitz, MD, PhD

The CEO and cofounder of Amprion spoke about additional diagnostic uses of the αSyn seed amplification assay and its validation in the Parkinson's Progression Markers Initiative study at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

5: Neurology News Network: Effective Symptom Control in Parkinson Disease

In this episode of Neurology News Network, Stuart H. Isaacson, MD, FAAN, offers insight into the challenges faced when attempting to achieve long-term symptom control for patients with Parkinson disease.